Biologics target inflammatory cytokines (TNF-α and IL-6) and cytokine receptors, interrupting the vicious cycle of inflammation, and are recommended even in early RA with low-severity inflammatory arthritis [91,112]. The gene discussed is TNF; the disease is rheumatoid arthritis.